Supplementary Digital Content 2: Table of Pediatric Antiretroviral Therapy Facility Characteristics Evaluated via Interview with Site-Level Program Managers*

	Sites N=29		Patients N=2,110	
	n	(%)	n	(%)
Site Size				
>100 ART patients aged <15 ever	5	17%	1,210	57%
≤100 ART patients aged <15 ever	24	83%	900	43%
Site Type				
Primary	21	72%	1,181	56%
Secondary	5	17%	231	11%
Tertiary	3	10%	698	33%
CD4 Testing Available On Site?				
Yes	14	48%	1,422	67%
No	15	52%	688	33%
Doctor Satisfaction with Work Environmen	nt			
Yes	18	62%	1,013	48%
No	11	38%	1,097	52%
Nurse Satisfaction with Work Environmen	t			
Yes	22	76%	1,419	67%
No	7	24%	691	33%
Any stock out of ARVs (1st or 2nd line) in l	ast year			
Yes	18	62%	955	45%
No	11	38%	1,155	55%
Nutritional Support at Site?				
Yes	11	38%	713	34%
No	18	62%	1,397	66%
General Pediatric In-Patient Care Available	e On Sit	e?		
Yes	17	59%	1,434	68%
No	12	41%	676	32%
Care for Tuberculosis Provided On Site?	_		3, 2	
Yes	14	48%	659	31%
No	15	52%	1,451	69%

Abbreviations: ARVs, antiretrovirals; ART, antiretroviral therapy.

^{*} The interviews were conducted during November 2009 through March 2010. If a site-level variable (e.g., availability of on-site CD4 testing) changed over time during 2004–2008, then the program manager was asked to estimate whether the majority of children enrolled on ART at his/her facility during 2004–2008 had been exposed to the site-level variable or not.